Mithra Pharmaceuticals SA
XBRU:MITRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (28.2), the stock would be worth €-2.14 (1 089% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -2.8 | €0.22 |
0%
|
| Industry Average | 28.2 | €-2.14 |
-1 089%
|
| Country Average | 13.8 | €-1.05 |
-585%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
€185.1m
|
/ |
Jan 2024
€-65m
|
= |
|
|
€185.1m
|
/ |
Dec 2024
€-24.4m
|
= |
|
|
€185.1m
|
/ |
Dec 2025
€19.4m
|
= |
|
|
€185.1m
|
/ |
Dec 2026
€50.4m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| BE |
|
Mithra Pharmaceuticals SA
XBRU:MITRA
|
14.9m EUR | -2.8 | -0.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 29.2 | 40.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 21.4 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 21.9 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 15.6 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 11.5 | 15.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.8 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 10.1 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 8.9 | 16.7 |
Market Distribution
| Min | 1.8 |
| 30th Percentile | 10 |
| Median | 13.8 |
| 70th Percentile | 19.8 |
| Max | 598.6 |
Other Multiples
Mithra Pharmaceuticals SA
Glance View
Mithra Pharmaceuticals SA operates as a Belgian biotech company, which engages in the development, manufacture, and commercialization of proprietary and differentiated drugs and generic products dedicated to female healthcare. The company is headquartered in Liege, Liege and currently employs 248 full-time employees. The company went IPO on 2015-06-30. The firm is a biotech company providing solutions in a field of women’s health, with a particular focus on contraception and menopause. Mithra’s goal is to develop products offering better efficacy, safety and convenience, meeting women’s needs throughout their life span. The firm provides three development candidates built on Mithra’s estrogen platform, Estetrol (E4): Estelle, a solution for oral contraception, PeriNesta, the oral treatment targeting perimenopause and Donesta, a hormone therapy. The firm also develops and manufactures therapeutics in the areas of contraception, menopause and hormone-dependent cancers. The company offers partners a spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. The firm operates in more than 100 countries around the world and is headquartered in Liege, Belgium.
